Novartis: FDA approves 40 mg Glatopa for multiple sclerosis
(CercleFinance.com) - The US Food and Drug Administration has approved the generic version of Teva's Copaxone for the treatment of relapsing forms of multiple sclerosis, Sandoz said on Tuesday.
The Novartis division consequently announced the launch of Glatopa 40 mg/mL as a fully-substitutable, AP-rated generic version of Copaxone three times weekly therapy for this indication.
Glatopa was developed under a collaboration agreement between Momenta Pharmaceuticals and Sandoz and is produced in the US.
Analysts at Bryan Garnier also note that Teva's fremanezumab - usually seen as the biggest threat against Novartis' erenumab for migraine treatment - was said to face a delay in its FDA approval due to manufacturing issues.
The Zurich-listed Novartis stock is currently down 0.5% at 78.5 Swiss francs.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Novartis division consequently announced the launch of Glatopa 40 mg/mL as a fully-substitutable, AP-rated generic version of Copaxone three times weekly therapy for this indication.
Glatopa was developed under a collaboration agreement between Momenta Pharmaceuticals and Sandoz and is produced in the US.
Analysts at Bryan Garnier also note that Teva's fremanezumab - usually seen as the biggest threat against Novartis' erenumab for migraine treatment - was said to face a delay in its FDA approval due to manufacturing issues.
The Zurich-listed Novartis stock is currently down 0.5% at 78.5 Swiss francs.
Copyright (c) 2018 CercleFinance.com. All rights reserved.